Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of atractylenolide I in preparation of medicine for protecting embryonic development of pregnancy complicated with diabetes mellitus

A technology of atractylodes lactone and embryonic development, which is applied in the direction of drug combination, disease, metabolic disease, etc., to achieve the effect of improving application value and expanding application range

Active Publication Date: 2021-12-21
JINAN UNIVERSITY
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, there are currently no safe oral medications to protect the development of embryos with gestational diabetes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of atractylenolide I in preparation of medicine for protecting embryonic development of pregnancy complicated with diabetes mellitus
  • Application of atractylenolide I in preparation of medicine for protecting embryonic development of pregnancy complicated with diabetes mellitus
  • Application of atractylenolide I in preparation of medicine for protecting embryonic development of pregnancy complicated with diabetes mellitus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0063] A certain concentration of atractyloid Ⅰ will not affect embryonic development

[0064] In order to determine whether Atractylolide Ⅰ has cytotoxic effect on embryonic development, early chick embryos were cultured by the method of Early chick Culture (EC Culture). The inventor added physiological saline in the culture medium as a control group; the final concentration of Atractylodes lactone I in the culture medium in the experimental group was 7.5 μM, 15 μM, and 30 μM respectively, and the chicken embryos of stage 0 (HH0) were incubated and harvested in 36 hours ( figure 2 A). Using the length of the embryo and the number of somites (the landmark structure for judging the early development stage of chicken embryos), the inventors found that 7.5 μM and 15 μM Atractylodes lactone Ⅰ had no significant effect on the development of chicken embryos, but 30 μM Atractylodes lactone Ⅰ The treatment significantly reduced the length of embryo development and the number of somi...

Embodiment 2

[0067] Atractylodes lactone Ⅰ can significantly improve embryonic death and developmental deformity induced by high glucose environment

[0068] Based on the chicken embryo model of gestational diabetes established by the inventor (Cell Cycle: 14(5):772-783.2015), the inventor set up a chicken embryo control group (normal saline), a high-sugar group (50mM glucose), and atractylodes lactone I low Concentration group (50mM glucose + 7.5μM Atractylodes lactone Ⅰ), atractylodes lactone Ⅰ medium concentration group (50mM glucose + 15μM Atractylodes lactone Ⅰ) a total of 4 groups, chicken embryos were cultured in the 4 groups of EC Culture to HH10 stage for development Statistics of period and deformity rate. The inventors compared the development of gastrula chick embryos exposed to normal saline, high sugar, and / or 7.5 μM and 15 μM Atractylodes lactone Ⅰ at the 36th hour of chicken embryo development ( image 3 A), the inventor found that the high-sugar environment can affect emb...

Embodiment 3

[0071] Atractylactone Ⅰ improves embryonic vascular failure caused by high glucose

[0072] The inventors used the chicken embryo YSM (yolk sac membrane) model to study whether Atractylolide Ⅰ can protect angiogenesis from being inhibited by high glucose (50mM glucose) ( Figure 4 A-D). The inventor set up a chicken embryo control group (normal saline), a high-sugar group (50mM glucose), atractylactone Ⅰ group (15μM atractylactone Ⅰ), a high-sugar + atractylactone Ⅰ group (50mM glucose+15μM atractylactone Ⅰ ) a total of 4 groups, incubate 0-day fertilized eggs for 2.5 days, take the rubber ring and stick it on the YSM, add the above solution to the rubber ring of the chicken embryo YSM in groups. After further culturing for 36 hours, the inventors found that compared with the angiogenesis of YSM in the control group ( Figure 4 A1-D1), the blood vessel density in the high glucose group was significantly reduced (P Figure 4 E), the blood vessel density of the 15 μM atractyloi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of atractylenolide I in preparation of a medicine for protecting embryonic development of pregnancy complicated with diabetes mellitus, belongs to the field of traditional Chinese medicines, and mainly relates to application of atractylenolide I as an effective component in preparation of a medicine for preventing and / or treating embryonic development diseases caused by pregnancy complicated with diabetes mellitus. It is found through a large number of experiments that atractylenolide I with a certain concentration does not cause embryonic development deformity, and can relieve embryonic cardiovascular system and nervous system dysplasia phenomena induced by a high-glucose environment effectively; and the atractylenolide I and a modifier synthesized by using the atractylenolide I as a lead compound can protect the development of pregnancy combined with glycosuria and embryonic cardiovascular system and nervous system.

Description

technical field [0001] The invention belongs to the field of traditional Chinese medicines, and in particular relates to the application of atractylodes lactone I in the preparation of medicines for protecting the embryonic development of pregnancy complicated with diabetes. Background technique [0002] In recent years, with the improvement of people's living standards and changes in eating habits and lifestyles, the incidence of gestational diabetes has been increasing year by year around the world, becoming a public health problem in various countries. Glucose can cross the placental barrier, and embryos with gestational diabetes mellitus are in a high-glucose environment. [0003] The incidence of gestational diabetes mellitus is increasing year by year in the context of the global obesity epidemic. The refinement and update of modern diagnostic criteria will further increase the prevalence of this disease. In recent years, with the opening of the three-child policy in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/365A61K36/284A61P15/00A61P3/10A61P9/00A61P25/00
CPCA61K31/365A61K36/284A61P15/00A61P3/10A61P9/00A61P25/00
Inventor 王广杨雪松张彤华
Owner JINAN UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com